Zobrazeno 1 - 10
of 216
pro vyhledávání: '"David G Strauss"'
Autor:
Christopher R Ellis, Rebecca Racz, Naomi L Kruhlak, Marlene T Kim, Alexey V Zakharov, Noel Southall, Edward G Hawkins, Keith Burkhart, David G Strauss, Lidiya Stavitskaya
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229646 (2020)
Kratom is a botanical substance that is marketed and promoted in the US for pharmaceutical opioid indications despite having no US Food and Drug Administration approved uses. Kratom contains over forty alkaloids including two partial agonists at the
Externí odkaz:
https://doaj.org/article/a24feac975674604922bfa76f58965bb
Autor:
Phu N Tran, Jiansong Sheng, Aaron L Randolph, Claudia Alvarez Baron, Nicolas Thiebaud, Ming Ren, Min Wu, Lars Johannesen, Donna A Volpe, Dakshesh Patel, Ksenia Blinova, David G Strauss, Wendy W Wu
Publikováno v:
PLoS ONE, Vol 15, Iss 11, p e0241362 (2020)
Buprenorphine is a μ-opioid receptor (MOR) partial agonist used to manage pain and addiction. QTC prolongation that crosses the 10 msec threshold of regulatory concern was observed at a supratherapeutic dose in two thorough QT studies for the transd
Externí odkaz:
https://doaj.org/article/bc6642b0a596431cad433e68b1c4b7cd
Correction: Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Autor:
Jose Vicente, Lars Johannesen, Meisam Hosseini, Jay W Mason, Philip T Sager, Esther Pueyo, David G Strauss
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0197952 (2018)
[This corrects the article DOI: 10.1371/journal.pone.0163619.].
Externí odkaz:
https://doaj.org/article/989426972b544a98bcaf026c2ec3d4cc
Autor:
Jose Vicente, Lars Johannesen, Meisam Hosseini, Jay W Mason, Philip T Sager, Esther Pueyo, David G Strauss
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0163619 (2016)
Drugs that prolong the heart rate corrected QT interval (QTc) on the electrocardiogram (ECG) by blocking the hERG potassium channel and also block inward currents (late sodium or L-type calcium) are not associated with torsade de pointes (e.g. ranola
Externí odkaz:
https://doaj.org/article/fc0f1c6356e94f23ac01ff3231f2fc02
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0166925 (2016)
Prolongation of the heart rate corrected QT (QTc) interval is a sensitive marker of torsade de pointes risk; however it is not specific as QTc prolonging drugs that block inward currents are often not associated with torsade. Recent work demonstrated
Externí odkaz:
https://doaj.org/article/826d341666a3403aa62d8b7c1f938e41
Autor:
David G Strauss, Douglas Schocken
Providing a solid foundation in current ECG technology as well as the newest diagnostic applications, Marriott's Practical Electrocardiography, Thirteenth Edition, delivers the information you need to quickly improve your ECG interpretive skills.
Autor:
Ryan De Palma, Vikram Patel, Jeffry Florian, David Keire, Daniela Selaya, David G. Strauss, Rodney Rouse, Murali K. Matta
Publikováno v:
Journal of Pharmaceutical Sciences. 112:1315-1323
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c3496fadd67e747e2092c9f429406ff
https://doi.org/10.1016/j.xphs.2023.01.026
https://doi.org/10.1016/j.xphs.2023.01.026
Autor:
Yow‐Ming Wang, David G. Strauss
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:11-15
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::179300f668c271cc51931423dd56667b
https://doi.org/10.1002/cpt.2782
https://doi.org/10.1002/cpt.2782
Autor:
Jeffry Florian, Qin Sun, Sarah J. Schrieber, Richard White, Sophie Shubow, Bernadette E. Johnson‐Williams, Morasa Sheikhy, Nicholas R. Harrison, Valerie J. Parker, Yow‐Ming Wang, David G. Strauss
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:1030-1035
The US Food and Drug Administration (FDA) Biosimilars Guidance describes how biosimilars may be approved based on clinical pharmacokinetic and pharmacodynamic (PD) biomarker data, without comparative clinical studies with efficacy end points. This ty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ee01dc7d97558b64e6fff597c2e7b94
https://doi.org/10.1002/cpt.2795
https://doi.org/10.1002/cpt.2795
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:55-61
A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from a US Food and Drug Administration (FDA)-approved reference product. The development and approval of biosimilars is critical to enhancing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d38cb0e36a2287192f7390a58399c681
https://doi.org/10.1002/cpt.2761
https://doi.org/10.1002/cpt.2761